Skip to search formSkip to main contentSkip to account menu
Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial
View on Elsevier
A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia
View on Elsevier
A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.
TLDR
PP did not demonstrate comparable efficacy to RIS-LAI, which may be attributable to the initiation dosing strategy employed, and Tolerability of both treatments was comparable to previous studies, with no new safety signals detected.
View on PubMed
Effect of early correction of anemia on the progression of CKD.
TLDR
The data suggest that normalization of hemoglobin levels in patients with CKD is safe and longer duration studies are needed to clarify efficacy benefits with high hemoglobin Levels.
View on PubMed
A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia
TLDR
Doses of once-monthly paliperidone palmitate offered the potential to improve outcomes in adults with symptomatic schizophrenia, both locally and systemically.
View on Nature
Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study
TLDR
Treatment with paliperidone palmitate (100 mg eq.) was efficacious and all doses tested were tolerable, and significant improvement in the Personal and Social Performance score from baseline to endpoint versus placebo.
View on Wolters Kluwer
Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
TLDR
Paliperidone ER (3-12 mg/day) treatment over a 30-week period was generally well-tolerated and may improve symptom severity in elderly patients with schizophrenia.
View on PubMed
Galantamine treatment of vascular dementia
TLDR
Galantamine was effective for improving cognition, including executive function, in patients with vascular dementia, with good safety and tolerability, however, improvement in activities of daily living with galantamines was similar to that observed with placebo.
View on Publisher
Low‐dose topiramate in adults with treatment‐resistant partial‐onset seizures
TLDR
Topiramate 200 mg/day is an appropriate target dose as adjunctive therapy in adults with treatment‐resistant partial‐onset seizures, even when receiving an enzyme‐inducing antiepileptic agent; 100’mg/ day also appears to be effective.
View on Wiley
Randomized Clinical Study of a Histamine H3 Receptor Antagonist for the Treatment of Adults with Attention-Deficit Hyperactivity Disorder
TLDR
Bavisant is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD.
View on Springer
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License